Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.

Each year, an estimated 590,000 infants acquire human immunodeficiency virus type 1 (HIV) infection from their mothers, mostly in developing countries that are unable to implement interventions now standard in the industrialized world. In resource-poor settings, the HIV pandemic has eroded hard-won gains in infant and child survival. Recent clinical trial results from international settings suggest that short-course antiretroviral regimens could significantly reduce perinatal HIV transmission worldwide if research findings could be translated into practice. This article reviews current knowledge of mother-to-child HIV transmission in developing countries, summarizes key findings from the trials, outlines future research requirements, and describes public health challenges of implementing perinatal HIV prevention interventions in resource-poor settings. Public health efforts must also emphasize primary prevention strategies to reduce incident HIV infections among adolescents and women of childbearing age. Successful implementation of available perinatal HIV interventions could substantially improve global child survival.

[1]  S. Gortmaker,et al.  Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. , 1999, JAMA.

[2]  J. Curran,et al.  Science, ethics, and future of research into maternal-infant transmission of HIV-1 , 1999, The Lancet.

[3]  D. Harris,et al.  RISK FACTORS FOR PERINATAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN WOMEN TREATED WITH ZIDOVUDINE , 1999 .

[4]  J. Goedert,et al.  Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission , 1996, The Lancet.

[5]  M. Kalish,et al.  Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. , 1999, AIDS.

[6]  Europeancollaborativestudy Risk factors for mother-to-child transmission of HIV-1. , 1992, Lancet.

[7]  D. Wara,et al.  Proposed definitions for in utero versus intrapartum transmission of HIV-1. , 1992, The New England journal of medicine.

[8]  K. Holmes,et al.  Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. , 1996, The American journal of tropical medicine and hygiene.

[9]  E. Cheraskin Mother–infant HIV transmission: Making the most of what we know , 1996, Nature Network Boston.

[10]  B. Hirschel,et al.  Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects , 1998, AIDS.

[11]  R. Biggar,et al.  Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in malawi: clinical trial , 1997, BMJ.

[12]  S. Spector,et al.  Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. , 1998, The Journal of infectious diseases.

[13]  P. Rustin,et al.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues , 1999, The Lancet.

[14]  P. Lurie,et al.  Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. , 1997, The New England journal of medicine.

[15]  L. Rodrigues,et al.  Late postnatal mother-to-child transmission of HIV-1 , 1998, The Lancet.

[16]  R. Biggar,et al.  HIV transmission through breastfeeding: a study in Malawi. , 1999, JAMA.

[17]  C. Giaquinto,et al.  Risk factors for mother‐to‐child transmission of HIV‐1 , 1992 .

[18]  L. Sokoll,et al.  Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. , 1999, The Journal of infectious diseases.

[19]  J. Karon,et al.  Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial , 1999, The Lancet.

[20]  L. Kuhn,et al.  Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. , 1999, Lancet.

[21]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[22]  T. Quinn,et al.  Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. , 1996, The Journal of infectious diseases.

[23]  L. Mofenson Mother-child HIV-1 transmission: Timing and determinants. , 1997, Obstetrics and gynecology clinics of North America.

[24]  R. Salamon,et al.  6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial , 1999, The Lancet.

[25]  F. Onyango,et al.  Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. , 2000, JAMA.

[26]  F. Dabis,et al.  Cost‐effectiveness and cost‐benefit in the prevention of mother‐to‐child transmission of HIV in developing countries , 1998 .

[27]  E. Karita,et al.  An assessment of the timing of mother-to-child transmission of human immunodeficiency virus type 1 by means of polymerase chain reaction. , 1994, Journal of acquired immune deficiency syndromes.

[28]  E. Karita,et al.  Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. , 1991, The New England journal of medicine.

[29]  Ijsselmuiden Cb Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. , 1998 .

[30]  A. Ades,et al.  Risk of human immunodeficiency virus type 1 transmission through breastfeeding , 1992, The Lancet.

[31]  L. Kalish,et al.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. , 1999, The New England journal of medicine.

[32]  Elliot Marseille,et al.  Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa , 1999, The Lancet.

[33]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[34]  L. Kalish,et al.  Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child , 1996, The New England journal of medicine.

[35]  H. Coovadia,et al.  Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study , 1999, The Lancet.

[36]  L. Mofenson,et al.  A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). , 1999, AIDS.

[37]  J. Ward,et al.  Trends in perinatal transmission of HIV/AIDS in the United States. , 1999, JAMA.

[38]  J. Karon,et al.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial , 1999, The Lancet.

[39]  Q. Karim Global Strategies for the Prevention of HIV Transmission from Mothers to Infants , 2000, Annals of the New York Academy of Sciences.

[40]  L. Hooper,et al.  Recent HIV seroprevalence levels by country: February 1999. , 1997 .

[41]  F. Dabis,et al.  Prevention of mother-to-child transmission of HIV in Africa: uptake of pregnant women in a clinical trial in Abidjan, Côte d'Ivoire. , 1998, AIDS.

[42]  S. Wiktor,et al.  Prevention of mother-to-child transmission of HIV-1 in Africa. , 1997, AIDS.

[43]  G. Duarte,et al.  Mode of delivery and the risk of vertical transmission of HIV-1. , 1999, New England Journal of Medicine.

[44]  M. Kalish,et al.  Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. , 1999, The Journal of infectious diseases.

[45]  H. Minkoff,et al.  The case for rapid HIV testing during labor. , 1998, JAMA.

[46]  E. Karita,et al.  Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. , 1991, Disease markers.

[47]  A. Nicoll,et al.  Infant feeding policy and practice in the presence of HIV-1 infection. , 1995, AIDS.

[48]  Philippe Van de Perre,et al.  International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection , 1998, The Lancet.

[49]  W. Graham,et al.  Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality , 1999, The Lancet.

[50]  H. Varmus,et al.  Ethical complexities of conducting research in developing countries. , 1997, The New England journal of medicine.

[51]  Families,et al.  Reducing the Odds: Preventing Perinatal Transmission of HIV In The United States , 1999 .